Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial (Q102060085)
Jump to navigation
Jump to search
scientific article published on 12 November 2020
Language | Label | Description | Also known as |
---|---|---|---|
English | Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial |
scientific article published on 12 November 2020 |
Statements
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial (English)
Phillip D Monk
Richard J Marsden
Victoria J Tear
Jody Brookes
Toby N Batten
Marcin Mankowski
Felicity J Gabbay
Donna E Davies
Ling-Pei Ho
Tristan Clark
Ratko Djukanovic
Tom M A Wilkinson
Inhaled Interferon Beta COVID-19 Study Group
12 November 2020